Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$33.88 USD
+0.59 (1.77%)
Updated Jul 19, 2024 04:00 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CORT 33.88 +0.59(1.77%)
Will CORT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CORT
Navigate Market Turbulence With These 4 Low-Beta Stocks
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Other News for CORT
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Interesting CORT Put And Call Options For February 2025
Corcept Therapeutics (CORT) Gets a Buy from Truist Financial